You are here: Industry Insights > Lenvatinib

News List

Breaking News! Chia Tai Tianqing to Receive Approval for another Generic in China PharmaSources/Caicai
March 26, 2021
The marketing application (acceptance No.: CYHS1900381) of Chia Tai Tianqing’s Class 4 generic drug has recently changed to the “Under approval” status, and the drug is expected to be approved for marketing this month ...
FDA Approves Carcinoma Treatment americanpharmaceuticalreview
July 23, 2021
The FDA approved pembrolizumab (Keytruda - Merck) in combination with lenvatinib (Lenvima, Eisai) for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) ...
Two new developments in kidney cancer treatments europeanpharmaceuticalreview
February 19, 2021
Studies suggest there are better treatment options than sunitinib for kidney cancers; cabozantinib in metastatic papillary kidney cancer and lenvatinib/pembrolizumab for renal cell carcinoma.
BDR Pharma launches generic version of Lenvatinib in India expresspharma
October 22, 2020
It is indicated for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer.
FDA Grants Accelerated Approval for Pembrolizumab plus Lenvatinib americanpharmaceuticalreview
September 19, 2019
The Food and Drug Administration (FDA) granted accelerated approval to the combination of pembrolizumab (KEYTRUDA, Merck) plus lenvatinib (LENVIMA, Eisai) for the treatment of patients with ...
Lenvima backed for NHS use to treat liver cancer pharmatimes
November 12, 2018
The Institute has issued a final appraisal document (FAD) recommending the use of Lenvima (lenvatinib) for untreated, advanced, unresectable hepatocellular carcinoma (HCC)
Eisai seeks marketing authorisation for lenvatinib from EMA pharmaceutical-technology
July 31, 2017
Eisai has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for first-line use of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC).